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Genes and Coronary Artery Disease
Where Are We?
Robert Roberts, MD, Alexandre F. R. Stewart, PHD
Ottawa, Ontario, Canada
Susceptibility to coronary artery disease (CAD) is claimed to be 40% to 60% inherited, but until recently genetic
risk factors predisposing to CAD have been elusive. Comprehensive prevention of CAD requires manipulation of
genetic risk. The availability of microarrays of single-nucleotide polymorphisms enabling genome-wide associa-
tion studies (GWAS) led to the discovery of 33 genetic risk variants for CAD. Surprisingly, 23 risk variants medi-
ate their risk through unknown mechanisms, with only 10 associating with hypertension or lipids. Thus, there are
several mechanisms contributing to the pathogenesis of CAD yet to be elucidated. The first risk variant discov-
ered by GWAS was 9p21.3, which occurs in 75% of all populations except African, with a mean increased risk of
25% per copy. Of the 33 variants for CAD, the increased risk varies from 6% to 92% with a mean increased risk
of 18%, occurring on average in 47% of the population. The maximum number of risk alleles per individual
would be 66. In the CARDIoGRAM (Coronary Artery Disease Genome-wide Replication and Meta Analysis) study
of 23 variants, the average per individual was 17, the minimum 7, and the maximum 37. The top 10th percen-
tile has an odds ratio of 1.88 and the lowest percentile an odds ratio of 0.55. Routine genetic screening is un-
likely until management is improved by genetic testing. Risk variants should provide pathophysiological insights
and targets for novel therapy. While risk variants are less potent predictors of CAD, compared with biomarkers,
they have the advantage of not changing in one’s lifetime and are unaffected by diet, sex, age, or medication.
(J Am Coll Cardiol 2012;60:1715–21) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2011.12.062s
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oCoronary artery disease (CAD) is the number 1 killer in
the world and is felt to be largely preventable. Reduction
of known risk factors for CAD such as hypercholester-
olemia, hypertension, and smoking have been assessed in
multiple randomized placebo-controlled clinical trials
and is associated with 30% to 40% less clinical events
such as death and myocardial infarction (1). Epidemio-
logical and family studies have repeatedly shown that
genetic predisposition accounts for 40% to 60% of the
risk for CAD (2). Prevention and treatment of CAD to
be comprehensive would be expected to also include
modification of the effects of these genetic risk factors,
analogous to the current treatment of hypercholesterol-
emia, which is partly genetic and partly environmental.
The barrier (3) until 2005 was the lack of technology.
he first microarray having 500,000 single-nucleotide
olymorphisms (SNPs) as DNA markers became avail-
ble and within 5 years the results have been nothing
hort of remarkable. In total, over 1,319 genetic variants
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Genome-Wide Association Studies
and the Common Allele Hypothesis
Genome-wide association studies (GWAS) have used as
many as 1,000,000 SNPs, variants in DNA sequence that
occur at a frequency1% in a population, to genotype large
amples of unrelated individuals with common diseases and
ompare the frequencies of genetic variants to that in equally
arge samples of control individuals. Genetic variants occur-
ing at a higher frequency in cases than controls are
onsidered to associate with disease risk. The limitation of
he GWAS approach is the exceedingly high threshold
equired for an association due to potential false positives
rom the multiple testing of 1,000,000 SNPs. The threshold
f significance is a p value 0.05/1,000,000 or 5  108.
To further avoid false positives, it has become the standard
to require replication of these markers showing genome-
wide significance in an independent and appropriate popu-
lation of adequate sample size. This stringency demands
large sample sizes. To detect a risk variant that increases the
risk by 10%, occurring in 15% of the population, requires a
discovery sample size of 20,000 to provide 80% power and
a similar replication sample size. All 33 risk loci for CAD
discussed in this review satisfy this rigid requirement (4–11).
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33 Genetic Variants
Associated With
Increased Risk for CAD
Table 1 lists the 33 genetic vari-
ants that exhibited genome-wide
significance and have been repli-
cated in appropriate independent
populations. The first CAD risk
variant, 9p21, was published in
2007, and within 2 years, 11 more
novel genetic variants were mapped
showing increased risk for CAD
(12–16). It was evident from the results of these studies that
most genetic variants would have modest to minimal risk
effect. The sample size to detect more of these variants
Abbreviations
and Acronyms
CAD  coronary artery
disease
GWAS  genome-wide
association studies
LDLC  low-density
lipoprotein cholesterol
lncRNA  long noncoding
RNA
SNP  single-nucleotide
polymorphisms
Risk Loci for Coronary Artery Disease/Myocardial Infarction DiscovTable 1 Risk Loci for Coronary Artery Disease/Myocardial Infa
Chromosomal Location SNP Nearby
Loci that associate with cholesterol
1p32.3 rs11206510 PCSK9
1p13.3 rs599839 SORT1
2p21 Rs4299376 ABCG8
6q25.3 rs3798220 LPA
8q24.13 rs17321515 TRIB1
9q34.2* rs579459 ABO
11q23.3 rs964184 ZNF259, APOA
19p13.2 rs1122608 LDLR
Loci that associate with hypertension
10q24.32 rs12413409 CYP17A1, CNN
12q24.12 rs3184504 SH2B3
Loci that do not associate with known risk factors
1p32.2 rs17114036 PPAP2B
1q41 rs17465637 MIA3
2q33.1 rs6725887 WDR12
3q22.3 rs2306374 MRAS
5q31.1 Rs2706399 IL5
6p24.1 rs6903956 C6orf105
6p24.1 rs12526453 PHACTR1
6p21.31 rs17609940 ANKS1A
6q23.2 rs12190287 TCF21
7q22.3 rs10953541 BCAP29
7q32.2 rs11556924 ZC3HC1
9p21.3 rs4977574 CDKN2A, CDK
10p11.23 rs2505083 KIAA1462
10q11.21 rs1746048 CXCL12
10q23.31 rs1412444 LIPA
11q22.3 rs974819 PDGF
13q34 rs4773144 COL4A1, COL4
14q32.2 rs2895811 HHIPL1
15q25.1 rs3825807 ADAMTS7
17p13.3 rs216172 SMG6, SRR
17p11.2 rs12936587 RASD1, SMCR
17q21.32 rs46522 UBE2Z, GIP, A
21q22.11 rs9982601 MRPS6*The locus at 9q34.2 is associated with myocardial infarction, but not with coronary atherosclerosis.
CI  confidence interval; SNP  single-nucleotide polymorphism.would have to be greater than initially expected, which
enticed most of the investigators involved in performing
GWAS for CAD to pool their resources. This led to the
formation of an international consortium designed
CARDIoGRAM (Coronary Artery Disease Genome-wide
Replication and Meta Analysis) study and involved the
collaboration of 14 GWAS, each of which on its own had
previously been successful (17). This brought together many
disciplines and considerable expertise with a total sample
size of 86,995 individuals (22,233 cases vs. 64,762 controls)
of European ancestry. This involved investigators from the
United Kingdom, Germany, the United States, and Can-
ada. This consortium combined the resources of over $200
million to pursue the genetic risk responsible for CAD.
Genotyping was performed with the 1 million chip array
followed by imputation of over 2 million SNPs from the
by Genome-Wide Association StudiesDiscovered by Genome-Wide Association Studies
Risk Allele Frequency
(Allele) Odds Ratio (95% CI) Ref. #
0.82 (T) 1.15 (1.10–1.21) (22)
0.78 (A) 1.29 (1.18–1.40) (11)
0.33 (G) 1.08 (1.04–1.13) (19)
0.02 (C) 1.92 (1.48–2.49) (4,13)
0.54 (A) 1.10 (1.06–1.15) (19)
0.21 (C) 1.10 (1.07–1.13) (6)
3-A1 0.13 (G) 1.13 (1.10–1.16) (6)
0.77 (G) 1.14 (1.09–1.19) (22)
T5C2 0.89 (G) 1.12 (1.08–1.16) (6)
0.44 (T) 1.13 (1.08–1.18) (14,15)
0.91 (A) 1.17 (1.13–1.22) (6)
0.74 (C) 1.20 (1.12–1.30) (11)
0.15 (C) 1.16 (1.10–1.22) (22)
0.18 (C) 1.15 (1.11–1.19) (8)
0.52 (G) 1.07 (1.03–1.11) (19)
0.07 (A) 1.65 (1.44–1.90) (7)
0.67 (C) 1.13 (1.09–1.17) (22)
0.75 (G) 1.07 (1.05–1.10) (6)
0.62 (C) 1.08 (1.06–1.10) (6)
0.75 (C) 1.08 (1.05–1.11) (5)
0.62 (C) 1.09 (1.07–1.12) (6)
NRIL 0.46 (G) 1.25 (1.18–1.31) 1.37 (1.26–1.48) (5,9,10)
0.42 (C) 1.07 (1.04–1.09) (5,16)
0.87 (C) 1.33 (1.20–1.48) (11)
0.34 (T) 1.09 (1.07–1.12) (5,19)
0.29 (T) 1.07 (1.04–1.09) (5)
0.44 (G) 1.07 (1.05–1.09) (6)
0.43 (C) 1.07 (1.05–1.10) (6)
0.57 (A) 1.08 (1.06–1.10) (5,6)
0.37 (C) 1.07 (1.05–1.09) (6)
T 0.56 (G) 1.07 (1.05–1.09) (6)
, SNF8 0.53 (T) 1.06 (1.04–1.08) (6)
0.15 (T) 1.19 (1.13–1.27) (22)eredrction
Genes
5-A4-C
M2, N
N2B, A
A2
3, PEM
TP5G1
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association in the Discovery population were analyzed for
replication in an independent population with a sample size
of 56,682. Thirteen new genetic risk variants for CAD were
identified with confirmation of 10 previously identified risk
variants (6). In another study involving CARDIoGRAM
investigators, Reilly et al. (18) identified 2 novel variants, 1
for CAD ADAMTS7 and 1 for myocardial infarction, the
ABO blood group locus. This was followed by the results
from the Coronary Artery Disease (C4D) Genetics Con-
sortium (5), which identified 4 additional risk loci related to
CAD. This study also involved replication in an indepen-
dent population of Caucasians and East Asians. In the same
issue of Nature Genetics, Wang et al. (7) reported on the
identification of a genetic variant at 6p21, which increases
the risk for CAD in the Chinese population, but has no risk
effect in the Caucasian population. The IBC 50K CAD
Consortium, utilizing a 50K SNP array covering approxi-
mately 2,100 candidate genes, identified 3 additional novel
CAD loci (19).
Common Features of CAD Genetic Risk Variants
There are several common features that characterize genetic
risk factors.
• Eight of the variants mediate their risk through lipids and
another 2 through hypertension, with 23 loci acting
independently of known risk factors (5–7,9,10,18–22).
• The increased relative risk of each variant for CAD varies
from 6% to 92% with a mean increased risk of 18%.
• The frequency of these variants in the population
varies from 2% to 91% with a mean frequency of 47%.
• In CARDIoGRAM with the analysis of 23 loci, the
number of alleles per individual could vary from 0 to
46. We observed the average to be 17, with a maxi-
mum of 37 and minimum of 7.
• Most genetic risk variants exhibit higher risk in indi-
viduals with early onset than for those with late onset
of CAD.
• The top 10th percentile is associated with odds ratio
for CAD of 1.88 and the lowest percentile is associated
with an odds ratio of 0.55.
• Most of the genetic risk variants for CAD are located
in DNA sequences that do not code for protein.
Biological and Therapeutic Implication of Loci
That Do Not Associate With Known Risk Factors
Perhaps the most exciting result of the GWAS approach is
the observation that 23 of the 33 loci do not associate with
any known risk factor for CAD. The corollary being there
are other mechanisms contributing to the pathogenesis of
CAD, which have heretofore not been considered. While
the mechanisms through which these genetic factors medi-
ate their risk remains to be determined the results of the
GWAS have robustly indicated they do exist. Secondly, itprovides the impetus to search for clues that will ultimately
identify the molecular pathways through which the risk is
manifested. It is highly likely the 23 loci associated with
unknown mechanisms will act through a few common
molecular pathways. This is speculative but would be in
keeping with the observation that 8 of the risk variants act
through just 2 pathways: cholesterol and hypertension. The
utilization of these pathways to identify new targets for drug
therapy should be a worthy future pursuit. These findings
also emphasize the necessity of identifying genetic risk
factors to provide comprehensive prevention and treatment
of CAD.
Refining the Phenotype:
Distinguishing CAD From Myocardial Infarction
In all of the GWAS for CAD the phenotype has been either
CAD defined as 50% obstruction in 1 or more coronary
vessels as determined by coronary angiography or docu-
mented myocardial infarction. The phenotype of CAD has
consistently been used interchangeable with that of myo-
cardial infarction. This is because myocardial infarction is
almost always induced by the superimposition of a thrombus
on existing CAD (atherosclerosis). In the initial discovery of
9p21, the phenotype by the Ottawa Group (10) was the
presence of CAD on the basis of coronary angiography,
while the phenotype of the DeCode Group was myocardial
infarction (9). Because myocardial infarction seldom occurs
without atherosclerosis it is not surprising several studies
have since linked 9p21 to the phenotype of myocardial
infarction (23–26). Despite this commonality of CAD and
myocardial infarction, it is intuitive that some of the genetic
risk factors specifically predispose to CAD and others to
myocardial infarction. In an attempt to separate the 2
phenotypes, Dandona et al. (27) analyzed the genotypes of
950 patients with early onset CAD documented by angiog-
raphy with and without myocardial infarction. The associ-
ation of the 9p21 risk allele in patients having CAD without
myocardial infarction was compared with patients having
CAD and myocardial infarction. There was a strong asso-
ciation between the 9p21 risk allele and CAD with no
association of the risk allele with myocardial infarction. The
association of 9p21 with CAD and not with myocardial
infarction was also observed by Horne et al. (28), Reilly et
al. (18), and more recently by Ardissino et al. (29). In
support of 9p21 acting at the vessel wall is the finding that
9p21 is a significant risk factor for abdominal aortic aneu-
rysm (30) and atherosclerotic stroke (31,32).
In the Dandona et al. study (27) it was also observed that
9p21 in a dose-dependent relationship was strongly associ-
ated with the severity of CAD as determined by the number
of coronary vessels involved. Left main disease also corre-
lated with the dosage of 9p21 risk allele. The frequency of
the 9p21 risk allele was significantly less in individuals with
1-vessel disease compared to 2- or 3-vessel disease. Simi-
larly, results were observed in an independent population of
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have confirmed 9p21 as a predictor of the severity of CAD
(20,29,33). In contrast, Hinohara et al. (23) in a study
involving Japanese and Korean populations did not observe
any relationship between the dose of 9p21 and the number
of coronary vessels involved. However, the sample size
consisted of 77 cases with 1-vessel disease, 54 with 2-vessel
disease, and 46 with 3-vessel disease, which is inadequate to
determine whether 9p21 is or is not associated with severity
of CAD. In a study by Chen et al. (34) no relationship
between 9p21 and the severity of CAD was observed. The
sample of 212 cases was insufficient as indicated by the
authors. In a study by Anderson et al. (35) with a sample
size of 1,011 cases, the authors observed a strong relation-
ship between 9p21 and the presence of CAD but no
relationship between gene dose and the number of vessels.
All of the studies in which coronary angiography is
available consistently show that 9p21 mediates its risk by
acting at the vessel wall to influence atherosclerosis and is
not associated with myocardial infarction. In contrast, there
is not consistent agreement on whether 9p21 relates to the
progression and severity of CAD. All of the studies have
been cross sectional. A definitive solution to this problem
may require a prospective longitudinal follow up study with
adequate sample size including serial coronary angiograms.
Similar data indicate the ADAMTS7 risk allele acts at the
vessel wall influencing coronary atherosclerosis.
The recent identification of the ABO blood group locus
as a risk factor for myocardial infarction has important
epidemiological, historical, biological, and therapeutic im-
plications. In this CARDIoGRAM study by Reilly et al.
(18), a GWAS was performed in 4,372 patients with
documented CAD by angiography and confirmed myocar-
dial infarction and 2,739 patients with documented CAD
without myocardial infarction. Several markers at 9q34.2
showed a strong association with myocardial infarction but
no association with CAD. This association with myocardial
infarction was replicated in an independent population and
a meta-analysis of the combined sample showed markers at
9q34.2 to be associated with myocardial infarction with
genome-wide significance.
It has been claimed for decades that blood group O offers
protection from myocardial infarction compared with blood
groups A or B (36). The locus for these blood groups at 9q34.2
is responsible for a single gene. The A, B, and O are different
forms (alleles) of the same gene. The A and B genes encode for
a protein (alpha 1-3N-acetylgalactosaminyltransferase), which
transfers a carbohydrate molecule onto von Willebrand’s
factor. This modification slows the normal process of
proteolysis and prolongs the life of von Willebrand’s factor.
This predisposes to coronary thrombosis, which is presum-
ably the cause of the myocardial infarction. In contrast, the
O gene encodes for a transferase protein, which is mutated
and as a result lacks the activity to transfer the carbohydrate
onto von Willebrand’s factor, so individuals with blood
group O do not have increased risk for myocardial infarc- btion. This has important therapeutic implications for pa-
tients undergoing bypass surgery, angioplasty, and other
such procedures.
Functional Analysis of Genetic Risk Variants
A major goal for the future will be to elucidate the
mechanisms whereby genetic variants mediate their risk.
This will require great ingenuity as most of them are in
regulatory regions rather than protein coding genes. Regu-
latory regions are known to act on nearby and far-removed
genes on the same chromosome or even to act in trans on
enes on other chromosomes (37). It is also bothersome that
regulatory region not only acts at great distances, but also
n many targets. The genetic risk factor of which the most
s known is 9p21.3. Discussion of the functional studies on
p21.3 illustrates both the problems and a reason for the
ack of success.
requency and Risk Analysis
f the 9p21.3 Risk Locus
cPherson et al. (10) and Helgadottir et al. (9) indepen-
ently and simultaneously discovered the first common
AD risk variant located on chromosome 9p21.3, using the
WAS approach that was confirmed by many others
11,38). The 9p21.3 risk allele is carried by 75% of the
uropean population (50% heterozygous and 25% homozy-
ous risk) and confers risk for coronary atherosclerosis by an
nknown mechanism that is independent of known risk
actors (9,10,38). The risk for CAD is increased by 25% with
copy and 50% by 2 copies of the 9p21.3 risk allele. In
remature CAD, 9p21.3 increases the risk 2-fold (10). A
ecent meta-analysis concluded that the 9p21.3 risk locus
as significantly associated with early age of onset of heart
isease (21). The association of the 9p21.3 locus with CAD
isk has also been documented in other ethnic groups
ncluding Chinese (39), Korean (24), Japanese (23), Indian
40), and Pakistani (41), but surprisingly not among Afri-
ans (42), suggesting that selective pressure has maintained
his allele in non-African populations.
unctional Analysis of 9p21.3
he 9p21.3 locus also contributes to the risk of intracranial
nd abdominal aortic aneurysms (30), vascular dementia and
ate onset Alzheimer’s disease (43). It is also noteworthy
hat the 9p21.3 locus has been also associated with aggres-
ive periodontitis (44) and gout (45), diseases with a marked
nflammatory component. However, it should be noted that
he 9p21.3 risk allele did not associate with general markers
f inflammation, such as C-reactive protein among cases
ith CAD (46,47).
The 9p21.3 CAD risk allele is in a region of DNA that
as no sequences that encode for protein. The risk allele is
ontained in a long noncoding RNA (lncRNA) of 126,000
ps, referred to as ANRIL and officially known as
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October 30, 2012:1715–21 Genes and CADCDKN2BAS lncRNA, which is adjacent to genes encoding
the cyclin-dependent kinase inhibitors CDKN2A and
CDKN2B (48–50). The lncRNA is transcribed into several
alternate transcripts and expression of the 9p21.3 risk
allele is consistently associated with higher expression of the
CDKN2BAS lncRNA yet lower mRNA expression of the
nearby genes CDKN2A and CDKN2B (48–50). We have
shown that several conserved sequences in this region
contain enhancer elements (48), recently confirmed by
others (51). Targeted deletion of the 9p21.3 homologous
region in the mouse was associated with reduced expression
of CDKN2A, confirming this region contains regulatory
enhancers (52). However, these mice did not exhibit ath-
erosclerosis. Because there is only 50% homology of the
DNA sequences between man and mouse, it is possible the
9p21.3 risk allele only developed in higher primates and
involves a primate-specific pathway, or these results could
indicate the mechanism whereby 9p21.3 confers risk is not
confined to reduced CDKN2A expression. A recent report
used the technique of chromatin conformation capture to
identify a long-range interaction between conserved en-
hancer sequences at the 9p21.3 locus that remodel chroma-
tin in the vicinity of the genes encoding CDKN2A and
CDKN2B, methylthioadenosine phosphorylase (MTAP),
and affect the genes much further downstream of
interferon-1 (IFNW1) and interferon -21 (IFNA21)
51). Interferon -21, similar to 9p21.3 risk allele, is a gene
nique to higher primates. If its expression were associated
ith the 9p21.3 risk genotype, it would be the first evidence
f an inflammatory cytokine specifically associated with
ncreased risk of CAD and could account for the primate
pecificity of the risk locus.
hat Is the Clinical Utility
f GWAS CAD Risk Loci?
he recent excitement of identifying 33 genetic variants
ssociated with increased risk for CAD is yet to be realized
n managing patients. The mean increased relative risk of
ach variant is only 15%. Thus, any 1 variant is not likely to
dd much over that of available markers, particularly if
ncluding the family history. Because most individuals have
t least 15 to 20 of these risk variants, the total risk may be
he sum of their interactions. The other possibility is some
ynergistic gene-to-gene interactions may occur that are not
ccounted for in current estimates. The expected clinical
pplication is early detection, and stratification of those at
igher risk together with new and appropriate therapies for
reatment. The fact that 23 of the risk variants for CAD do
ot act through any of the known risk factors is very
romising and exciting. It indicates the pathogenesis of
AD is due to mechanisms yet to be elucidated. The best
lass of drugs currently to prevent CAD is the statins, which
ecrease the synthesis of cholesterol. This pathway came
nto the limelight with the recognition that the gene that
ncodes the receptor for cholesterol was abnormal in famil- pal hypercholesterolemia, a rare disorder (1 in 5,000 indi-
iduals) (53). It would be a decade before a drug would be
arketed, however, progress is likely to be more rapid
oday. Given there are 23 variants acting through unknown
echanisms, it is highly likely another pathway equivalent
o that of the cholesterol is waiting to be identified. The
ssue of genetics for early detection and prevention is more
omplex. On the basis of the known 33 genetic risk variants,
he maximum number an individual could have if homozy-
ous for all alleles is 66. In the CARDIoGRAM study (6),
e analyzed 23 variants (46 alleles) and observed an average
f 17 per individual, with a minimum of 7 and a maximum
f 37. There are some advantages of genetic DNA variants
ver that of conventional biomarkers such as cholesterol.
hile cholesterol varies with sex, age, diet, and preferably
etected during fasting, DNA variants do not change in the
ifetime of the individual and does not vary with meals or
rugs, thus 1 blood sample at birth is all that is needed.
owever, cholesterol is a much stronger predictor of CAD
han any of the genetic variants.
Are these genetic variants ready for routine testing? The
hort answer is no and likely to remain as such until it is
roven that their application in some way improves patient
anagement. If we have to wait until specific treatment is
vailable it will require several years. The time from discov-
ry of the defective gene encoding the cholesterol receptor
ntil the first statin was available was almost 20 years. We
ould expect today that once a mechanism is discovered, it
ould not take so long to develop appropriate therapy.
owever, the increased risk of these variants is significant
nd because most are acting through unknown mechanisms,
here is increased excitement and enthusiasm to adopt
enetic testing. Fifty percent of the population has blood
roup A or B, which is associated with increased risk of MI,
ith implications for increased thrombosis after bypass
urgery or angioplasty. Would it be prudent for individuals
f group A or B to receive aspirin daily? One approach to
tilizing 9p21 to alter management could be on the basis of
he ATP III (Adult Treatment Panel III) recommendations
or treatment of low-density lipoprotein cholesterol
LDLC). The recommendations are to treat LDLC exceed-
ng 190 mg/dl if the individual has only 1 risk factor and to
reat LDLC of 160 mg/dl with 2 risk factors. There is
onsistent agreement that 9p21 is an independent risk factor
nd thus would change the levels of LDLC required for
tatin therapy. This could be considered for approval by the
TP Committee before development of new therapy.
The risk associated with 9p21.3 for individuals likely to
et CAD before the age of 55 years (males) and 60 for
emales is twofold greater. This is equivalent to many risk
actors such as smoking. Several investigators have ques-
ioned the clinical utility of GWAS loci as a standalone
pproach to predict risk in the context of CAD (54,55).
owever, among patients after coronary artery bypass graft-
ng, the ability to predict mortality was significantly im-
roved by genotyping for the 9p21.3 risk locus (56).
1720 Roberts and Stewart JACC Vol. 60, No. 18, 2012
Genes and CAD October 30, 2012:1715–21Furthermore, using 12 GWAS variants, we found that these
significantly improved prediction of CAD over traditional
risk factors (57). With the accrual of additional risk loci,
perhaps in combination with the detection of serum bio-
markers that might be discovered to associate with these risk
loci, GWAS risk loci are likely to have even greater power
to predict disease severity and age at onset. What is the
major barrier to genetic testing for CAD? It is not a
technological problem. One can put 30 or 200 risk variants
on a chip and have the result within an hour with today’s
technology. The interpretation can be produced immedi-
ately and such algorithms are already available. The real
barrier is that no specific treatment exists as of yet. Until the
mechanisms are discovered and management is improved,
genetic testing is unlikely to become routine. The discovery
of 33 genetic risk variants for CAD and the increased
awareness of prevention will no doubt catalyze the search for
improved treatments and the elucidation of their biology
and pathophysiology.
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